Meeting Banner
Abstract #4742

Quantitative MRI in a Phase 1 Clinical Study of the Vascular Disrupting Agent Crolibulin

Andres Arias Lorza1, Harshan Ravi1, Rohit Philip2, Jean-Philippe Galons2, Theodore Trouard2, Nestor Parra1, William Read3, Raoul Tibes4, Ronald Korn5, and Natarajan Raghunand1
1Moffitt Cancer Center, Tampa, FL, United States, 2University of Arizona, Tucson, AZ, United States, 3Emory University School of Medicine, Atlanta, GA, United States, 4Perlmutter Cancer Center, New York, NY, United States, 5Imaging Endpoints, Scottsdale, AZ, United States

Diffusion and DCE-MRI were performed at baseline and 2-3 days following Crolibulin (EPC2407) treatment in a phase 1 clinical study of this vascular disrupting agent (VDA). Several functional parameter maps were computed and co-registered across scan dates in 11 subjects with advanced solid tumors. We measured changes in these MRI parameters that indicate cell swelling and vascular reduction following treatment. We identified multivariate combinations of changes in these MRI parameters that are correlated with the dose, AUC and Cmax of Crolibulin, respectively, information that can guide Crolibulin dosing in clinical trials of this VDA in combination with cytotoxic drugs.

This abstract and the presentation materials are available to members only; a login is required.

Join Here